

# Clinical validity of circulating tumour cells in patients with metastatic colorectal cancer: a pooled analysis of individual patient data

Lancet Oncology, The  
15, 406-414

DOI: [10.1016/s1470-2045\(14\)70069-5](https://doi.org/10.1016/s1470-2045(14)70069-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical utility of circulating tumor cell counting through CellSearch®; the dilemma of a concept suspended in Limbo. <i>OncoTargets and Therapy</i> , 2014, 7, 619.	1.0	37
2	By the Numbers: Does Circulating Tumor Cell Enumeration Have a Role in Metastatic Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3479-3482.	0.8	5
3	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. <i>Personalized Medicine</i> , 2014, 11, 545-558.	0.8	8
5	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	2.2	94
6	Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	86
8	Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3470-3471.	0.8	23
9	Prognostic and Predictive Role of Circulating Tumor Cells in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 251-259.	0.5	1
11	Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. <i>Annals of Oncology</i> , 2014, 25, 2304-2313.	0.6	138
12	Challenges in circulating tumour cell research. <i>Nature Reviews Cancer</i> , 2014, 14, 623-631.	12.8	1,102
13	American association for cancer research " AACR congress 2014. <i>Oncologie</i> , 2014, 16, 341-366.	0.2	0
14	Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 345-351.	1.1	16
16	Circulating tumour cells: telling the truth about metastasis. <i>Lancet Oncology</i> , The, 2014, 15, 365-366.	5.1	19
17	Molecular profiling of single circulating tumor cells with diagnostic intention. <i>EMBO Molecular Medicine</i> , 2014, 6, 1371-1386.	3.3	218
18	Circulating tumor cells before and during follow-up after breast cancer surgery. <i>International Journal of Oncology</i> , 2015, 46, 407-413.	1.4	52
19	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015. <i>Breast Care</i> , 2015, 10, 199-205.	0.8	10
20	A Versatile Microarray Platform for Capturing Rare Cells. <i>Scientific Reports</i> , 2015, 5, 15342.	1.6	36
23	Liquid biopsy. <i>Current Opinion in Oncology</i> , 2015, 27, 560-567.	1.1	35
24	Micrometastatic Circulating Tumor cells; A Challenge for an Early Detection and Better Survival Rates. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2015, 06, .	0.3	0

#	ARTICLE	IF	CITATIONS
25	Current Understanding of Circulating Tumor Cells â€“ Potential Value in Malignancies of the Central Nervous System. <i>Frontiers in Neurology</i> , 2015, 6, 174.	1.1	20
26	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015, 10, e0140712.	1.1	580
27	Characterization of DNA Methylation in Circulating Tumor Cells. <i>Genes</i> , 2015, 6, 1053-1075.	1.0	46
28	Genomic profiling of breast cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 34-39.	0.9	19
29	A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. <i>Journal of Translational Medicine</i> , 2015, 13, 126.	1.8	23
30	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 974-982.	1.5	155
31	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	3.2	78
32	Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. <i>Pharmacogenomics</i> , 2015, 16, 669-672.	0.6	1
33	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 1-3.	0.9	0
34	Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 339-349.	1.1	57
35	Clinical relevance of circulating tumor cells in cancer patients. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 227-230.	0.3	1
36	Sampling circulating tumor cells for clinical benefits: how frequent?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 75.	6.9	19
37	Quantitative detection of circulating tumor-derived mitochondrial NADH subunit variants as a potential prognostic biomarker for oral cancer. <i>International Journal of Oncology</i> , 2015, 47, 1077-1083.	1.4	12
38	Circulating tumor cell enumeration by the CellSearch system: The clinicianâ€™s guide to breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 144-150.	3.4	62
39	Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. <i>Clinical Cancer Research</i> , 2015, 21, 1298-1304.	3.2	56
40	Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer?. <i>Clinical Cancer Research</i> , 2015, 21, 2421-2423.	3.2	9
41	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. <i>Cancer Research</i> , 2015, 75, 892-901.	0.4	321
42	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80

#	ARTICLE	IF	CITATIONS
43	High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. <i>Lab on A Chip</i> , 2015, 15, 2090-2101.	3.1	62
44	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 2.	2.2	36
45	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. <i>Breast Cancer Research</i> , 2015, 17, 3.	2.2	48
46	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer – Advancing from Prognostic to Predictive Potential. <i>Current Breast Cancer Reports</i> , 2015, 7, 53-58.	0.5	0
47	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , 2015, 367, 43-48.	3.2	34
48	Biomarkers in Breast Cancer. <i>Advances in Clinical Chemistry</i> , 2015, 71, 1-23.	1.8	86
49	Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1622-1622.	0.8	22
50	Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial. <i>Cancer Letters</i> , 2015, 360, 213-218.	3.2	45
51	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
52	May CTC technologies promote better cancer management?. <i>EPMA Journal</i> , 2015, 6, 1.	3.3	31
53	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. <i>Annals of Oncology</i> , 2015, 26, 1704-1709.	0.6	18
54	Biomarkers as Prognostic, Predictive, and Surrogate Endpoints. <i>Current Clinical Pathology</i> , 2015, , 31-41.	0.0	2
55	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. <i>BMC Cancer</i> , 2015, 15, 403.	1.1	70
57	Efficient microfluidic negative enrichment of circulating tumor cells in blood using roughened PDMS. <i>Analyst, The</i> , 2015, 140, 3565-3572.	1.7	44
58	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 41-50.	0.8	75
59	Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 232-237.	0.8	19
60	Accessing Genetic Information with Liquid Biopsies. <i>Trends in Genetics</i> , 2015, 31, 564-575.	2.9	121
61	Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1411-1417.	1.5	43

#	ARTICLE	IF	CITATIONS
62	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. <i>Cancer Cell</i> , 2015, 28, 666-676.	7.7	700
63	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. <i>Clinical Cancer Research</i> , 2015, 21, 4786-4800.	3.2	310
64	The Role of CTCs as Tumor Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 341-367.	0.8	80
65	Clinical and molecular complexity of breast cancer metastases. <i>Seminars in Cancer Biology</i> , 2015, 35, 85-95.	4.3	118
66	Retrieval of Disseminated Tumor Cells Colonizing the Bone in Murine Breast Cancer Metastasis Models. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 103-108.	1.0	4
67	Biological markers of invasive breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 153-153.	0.6	23
69	Breast Cancer Update 2014 – Focus on the Patient and the Tumour. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 170-182.	0.8	9
73	En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. <i>Trends in Cancer</i> , 2015, 1, 44-52.	3.8	218
75	Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. <i>Tumor Biology</i> , 2015, 36, 6653-6665.	0.8	38
76	Liquid biopsy for cancer patients: Principles and practice. <i>Pathogenesis</i> , 2015, 2, 1-4.	0.8	31
77	Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 281-281.	3.0	3
78	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 563-571.	1.1	124
79	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
80	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	3.2	35
81	Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: The METAL3 Study. <i>Contemporary Clinical Trials</i> , 2015, 40, 1-8.	0.8	10
82	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 278-289.	1.5	19
83	Biology, detection, and clinical implications of circulating tumor cells. <i>EMBO Molecular Medicine</i> , 2015, 7, 1-11.	3.3	453
84	Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. <i>International Journal of Cancer</i> , 2015, 136, 2158-2165.	2.3	136

#	ARTICLE	IF	CITATIONS
85	The steady progress of targeted therapies, promising advances for lung cancer. <i>Ecanermedicalscience</i> , 2016, 10, 638.	0.6	6
86	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. <i>Oncotarget</i> , 2016, 7, 26107-26119.	0.8	136
87	Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. <i>Oncotarget</i> , 2016, 7, 48625-48643.	0.8	53
88	Circulating Tumor Cells as an Indicator of Postoperative Lung Cancer: A Case Report. <i>American Journal of Case Reports</i> , 2016, 17, 663-665.	0.3	2
89	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. <i>Oncotarget</i> , 2016, 7, 66880-66891.	0.8	54
90	Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 115-124.	1.3	20
91	Tumoral heterogeneity of breast cancer. <i>Annales De Biologie Clinique</i> , 2016, 74, 653-660.	0.2	53
92	Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1665.	1.8	63
93	A FISH-based method for assessment of &lt;em>&gt;HER-2&lt;/em> amplification status in breast cancer circulating tumor cells following CellSearch isolation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7095-7103.	1.0	17
94	Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. <i>Frontiers in Oncology</i> , 2016, 6, 255.	1.3	32
95	Circulating Tumor Cells in the Adenocarcinoma of the Esophagus. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1266.	1.8	13
96	Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1775.	1.8	58
97	Circulating tumor cells in breast cancer patients. <i>Neoplasma</i> , 2016, 63, 18-29.	0.7	10
98	The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 37361-37369.	0.8	27
99	Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A-trial. <i>BMC Cancer</i> , 2016, 16, 401.	1.1	14
100	EMT: 2016. <i>Cell</i> , 2016, 166, 21-45.	13.5	3,573
101	Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. <i>Breast Cancer Research</i> , 2016, 18, 118.	2.2	65
102	Current role of liquid biopsy in metastatic breast cancer and future perspectives. <i>Der Gynakologe</i> , 2016, 49, 680-684.	1.0	0

#	ARTICLE	IF	CITATIONS
103	Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 129.	2.2	85
104	Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. <i>BMC Cancer</i> , 2016, 16, 433.	1.1	125
105	The promise of circulating tumor cells for precision cancer therapy. <i>Biomarkers in Medicine</i> , 2016, 10, 1269-1285.	0.6	11
106	Circulating Tumor Cells. , 2016, , 219-234.		0
107	Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. <i>Scientific Reports</i> , 2016, 6, 24517.	1.6	131
108	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK Positive Non-Small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2016, 17, e173-e177.	1.1	22
109	Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1037-1042.	1.1	61
110	Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients. <i>Clinical Chemistry</i> , 2016, 62, 1002-1011.	1.5	54
111	Noninvasive strategies for breast cancer early detection. <i>Future Oncology</i> , 2016, 12, 1395-1411.	1.1	13
112	Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. <i>Pharmacogenomics</i> , 2016, 17, 183-186.	0.6	24
113	Signatures of breast cancer metastasis at a glance. <i>Journal of Cell Science</i> , 2016, 129, 1751-8.	1.2	52
114	CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210.	3.2	28
115	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 329-338.	1.1	18
116	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. <i>Current Breast Cancer Reports</i> , 2016, 8, 60-72.	0.5	1
117	Cryopreservation of Circulating Tumor Cells for Enumeration and Characterization. <i>Biopreservation and Biobanking</i> , 2016, 14, 330-337.	0.5	6
118	The Mechanisms of Breast Cancer Metastasis. , 2016, , 135-148.		1
119	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. <i>Current Problems in Cancer</i> , 2016, 40, 117-129.	1.0	1
120	A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. <i>International Journal of Cancer</i> , 2016, 138, 2894-2904.	2.3	155

#	ARTICLE	IF	CITATIONS
121	Breast cancer stem cells: are we ready to go from bench to bedside?. <i>Histopathology</i> , 2016, 68, 119-137.	1.6	35
122	Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 743-755.	1.7	34
123	Current and emerging therapies of HER2-positive metastatic breast cancer. <i>Breast</i> , 2016, 29, 170-177.	0.9	20
125	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016, 76, 5954-5961.	0.4	16
126	Analytical evaluation for somatic mutation detection in circulating tumor cells isolated using a lateral magnetophoretic microseparator. <i>Biomedical Microdevices</i> , 2016, 18, 91.	1.4	6
127	Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer. <i>Oncology</i> , 2016, 91, 48-54.	0.9	19
128	Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. <i>Science Advances</i> , 2016, 2, e1600274.	4.7	120
129	Detection of circulating tumour cells may add value in endometrial cancer management. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 207, 1-4.	0.5	16
130	Circulating tumor cells in breast cancer: applications in personalized medicine. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 411-424.	1.1	44
131	MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. <i>Scientific Reports</i> , 2016, 6, 28929.	1.6	39
132	Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 526.	1.1	28
133	Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1772-1779.	0.5	45
134	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	1.1	25
135	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e11-235.e16.	0.8	62
136	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 936-944.	0.8	17
137	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 418-430.	2.1	150
138	Functional studies on circulating and disseminated tumor cells in carcinoma patients. <i>Molecular Oncology</i> , 2016, 10, 443-449.	2.1	60
139	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 39-50.	1.5	11



#	ARTICLE	IF	CITATIONS
140	Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2197-2206.	3.2	135
141	Functional Studies on Viable Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 328-334.	1.5	87
142	Review: circulating tumor cells in the practice of breast cancer oncology. <i>Clinical and Translational Oncology</i> , 2016, 18, 749-759.	1.2	7
143	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	1.9	20
144	Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 235-258.	0.8	69
146	In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. <i>Breast Cancer Research</i> , 2016, 18, 30.	2.2	129
147	Prognostic Implications of CTC in Breast Cancer. <i>Current Cancer Research</i> , 2016, , 233-254.	0.2	0
148	CTC in Advanced Breast Cancer Prognosis, Monitoring, and Clinical Utility. <i>Current Cancer Research</i> , 2016, , 257-270.	0.2	0
149	Les biomarqueurs circulants du cancer : avantages et perspectives. <i>Revue Francophone Des Laboratoires</i> , 2016, 2016, 51-57.	0.0	0
150	Genesis of Circulating Tumor Cells Through Epithelial-Mesenchymal Transition as a Mechanism for Distant Dissemination. <i>Current Cancer Research</i> , 2016, , 139-182.	0.2	5
151	Clinical and biological significance of circulating tumor cells in cancer. <i>Molecular Oncology</i> , 2016, 10, 408-417.	2.1	113
152	Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. <i>Molecular Oncology</i> , 2016, 10, 481-493.	2.1	75
153	Liquid biopsy: Potential and challenges. <i>Molecular Oncology</i> , 2016, 10, 371-373.	2.1	67
154	Making cancer visible – Dyes in surgical oncology. <i>Surgical Oncology</i> , 2016, 25, 30-36.	0.8	10
155	Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , .	0.2	6
156	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087
157	Liquid Biopsy in Metastasized Breast Cancer as Basis for Treatment Decisions. <i>Oncology Research and Treatment</i> , 2016, 39, 112-116.	0.8	22
158	Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 81-90.	2.0	7

#	ARTICLE	IF	CITATIONS
159	Challenges in circulating tumor cell detection by the CellSearch system. <i>Molecular Oncology</i> , 2016, 10, 395-407.	2.1	231
160	Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. <i>Expert Review of Proteomics</i> , 2016, 13, 201-211.	1.3	6
161	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2583-2593.	3.2	289
162	Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 25-38.	1.5	30
163	Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 271-281.	0.8	45
164	Circulating tumor cells in breast cancer—current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 22-29.	2.0	36
165	Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. <i>International Journal of Cancer</i> , 2016, 138, 1586-1600.	2.3	12
166	Progress of Circulating Tumor Cells in Cancer Management. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 509-516.	0.8	3
167	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. <i>Clinical Cancer Research</i> , 2017, 23, 88-96.	3.2	186
168	Translating genomic profiling to gastrointestinal cancer treatment. <i>Future Oncology</i> , 2017, 13, 919-934.	1.1	7
169	Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. <i>Breast</i> , 2017, 32, 119-125.	0.9	19
170	Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. <i>Scientific Reports</i> , 2017, 7, 42517.	1.6	69
171	Circulating tumor cells: clinical validity and utility. <i>International Journal of Clinical Oncology</i> , 2017, 22, 421-430.	1.0	170
172	Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. <i>Growth Hormone and IGF Research</i> , 2017, 33, 28-34.	0.5	10
173	Human circulating and tissue gastric cancer stem cells display distinct epithelial—mesenchymal features and behaviors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1687-1699.	1.2	5
174	Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis. <i>Oncology Reports</i> , 2017, 37, 3219-3226.	1.2	11
175	Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. <i>Translational Research</i> , 2017, 185, 58-84.e15.	2.2	124
176	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 869-870.	2.8	8

#	ARTICLE	IF	CITATIONS
177	Characterization of single circulating tumor cells. FEBS Letters, 2017, 591, 2241-2250.	1.3	48
178	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. Seminars in Cancer Biology, 2017, 44, 106-116.	4.3	47
179	Circulating Tumor Cells in Gastric Cancer. , 2017, , 35-43.		0
180	<scp>EMT</scp>: Present and future in clinical oncology. Molecular Oncology, 2017, 11, 718-738.	2.1	205
181	Cell line dependent expression of EpCAM influences the detection of circulating tumor cells with CellSearch. Laryngoscope Investigative Otolaryngology, 2017, 2, 194-198.	0.6	5
182	Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples â€“ a short report. Cellular Oncology (Dordrecht), 2017, 40, 511-519.	2.1	5
184	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. Advances in Experimental Medicine and Biology, 2017, 994, 1-41.	0.8	20
185	Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 181-203.	0.8	19
186	Strategies for Isolation and Molecular Profiling of Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 43-66.	0.8	5
189	Epithelial-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs): The Traveling Metastasis. Cancer Drug Discovery and Development, 2017, , 67-80.	0.2	2
190	Enumeration and Molecular Analysis of CTCs in Metastatic Disease: The Breast Cancer Model. Cancer Drug Discovery and Development, 2017, , 41-65.	0.2	0
191	CTCs and ctDNA: Two Tales of a Complex Biology. Cancer Drug Discovery and Development, 2017, , 119-137.	0.2	1
192	Epithelial-mesenchymal plasticity in circulating tumor cells. Journal of Molecular Medicine, 2017, 95, 133-142.	1.7	113
193	Classifying circulating tumor cells to monitor cancer progression. Expert Review of Molecular Diagnostics, 2017, 17, 153-165.	1.5	9
194	Liquid Biopsy: A Future Tool for Posttreatment Surveillance in Head and Neck Cancer?. Pathobiology, 2017, 84, 115-120.	1.9	27
195	Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters. Clinical Cancer Research, 2017, 23, 1722-1732.	3.2	26
196	Exploratory analysis of local gene groups in breast cancer guided by biological networks. Health and Technology, 2017, 7, 119-132.	2.1	0
197	New Strategies in Metastatic Hormone Receptorâ€“Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. Clinical Cancer Research, 2017, 23, 1126-1131.	3.2	11

#	ARTICLE	IF	CITATIONS
198	A disposable microfluidic device with a reusable magnetophoretic functional substrate for isolation of circulating tumor cells. <i>Lab on A Chip</i> , 2017, 17, 4113-4123.	3.1	37
199	The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. <i>Pathobiology</i> , 2017, 84, 264-283.	1.9	16
200	Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 542-557.	2.3	28
201	Targeting epithelialâ€mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. <i>Biochemical Journal</i> , 2017, 474, 3269-3306.	1.7	53
202	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. <i>European Journal of Cancer</i> , 2017, 83, 185-193.	1.3	19
203	Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases. <i>Scientific Reports</i> , 2017, 7, 7196.	1.6	33
204	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
205	Circulating tumor cell count and thrombosis in metastatic breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1981-1988.	1.9	11
206	Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. <i>Cancer Research</i> , 2017, 77, 4530-4541.	0.4	44
207	Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. <i>Tumor Biology</i> , 2017, 39, 101042831773151.	0.8	20
208	Liquid Biopsy: Current Status and Future Perspectives. <i>Oncology Research and Treatment</i> , 2017, 40, 404-408.	0.8	177
209	Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 733-741.	1.1	27
210	Pattern of metastatic spread and subcategories of breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 211-223.	0.8	21
211	Integrated bio-affinity nano-platform into a microfluidic immunosensor based on monoclonal bispecific trifunctional antibodies for the electrochemical determination of epithelial cancer biomarker. <i>Clinica Chimica Acta</i> , 2017, 464, 64-71.	0.5	33
212	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 83-94.	1.1	156
213	Circulating and disseminated tumour cells â€mechanisms of immune surveillance and escape. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 155-167.	12.5	426
214	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 17307.	1.6	16
215	Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma â€What is the Role of Liquid Biopsy in Breast Cancer?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1291-1298.	0.8	18

#	ARTICLE	IF	CITATIONS
216	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	3.6	49
217	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	9
218	Flüssigbiopsie: Status quo und Zukunftsperspektiven. <i>Karger Kompass Pneumologie</i> , 2017, 5, 206-210.	0.0	0
219	Circulating Tumor Cells in Breast Cancer: A Potential Liquid Biopsy. , 2017, , .		3
220	Techniques for maximizing the performance of molecular pathology testing: responsibilities of all pathologists. <i>Turk Patoloji Dergisi</i> , 2017, 34, 113-126.	0.1	1
221	Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1363-1373.	1.0	33
222	A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1885.	1.8	37
223	Microdevices for Non-Invasive Detection of Bladder Cancer. <i>Chemosensors</i> , 2017, 5, 30.	1.8	8
224	Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. <i>International Journal of Molecular Sciences</i> , 2017, 18, 363.	1.8	39
225	Circulating Tumor Cells: Back to the Future. <i>Frontiers in Oncology</i> , 2017, 6, 275.	1.3	3
226	Big data analytics in healthcare: opportunities, challenges and techniques. <i>International Journal of Social Computing and Cyber-Physical Systems</i> , 2017, 2, 35.	0.1	0
227	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017, 8, 109818-109835.	0.8	5
228	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	0.8	42
229	Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2413-2424.	1.0	16
230	Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 67918-67932.	0.8	9
231	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 55632-55645.	0.8	116
232	Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, S1346-S1358.	0.6	18
233	Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. <i>Cancer Genetics</i> , 2018, 228-229, 159-168.	0.2	36

#	ARTICLE	IF	CITATIONS
234	The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 66, 56-63.	3.4	24
235	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	3.0	206
236	Clinical indications for, and the future of, circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 143-150.	6.6	57
237	Change in Topoisomerase 1α Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , 2018, 24, 3348-3357.	3.2	18
238	Les cellules tumorales circulantes comme biopsie liquide du cancer. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 75-80.	0.0	0
239	Clinical applications of the CellSearch platform in cancer patients. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 102-121.	6.6	185
240	Profiling circulating tumour cells and other biomarkers of invasive cancers. <i>Nature Biomedical Engineering</i> , 2018, 2, 72-84.	11.6	187
241	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. <i>Pathobiology</i> , 2018, 85, 23-34.	1.9	65
242	Epithelial Mesenchymal Transition in Tumor Metastasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 395-412.	9.6	896
243	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. <i>British Journal of Surgery</i> , 2018, 105, e158-e168.	0.1	32
244	Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer. , 2018, , 858-866.e3.		2
245	ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 1500-1510.	3.2	125
246	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 122-131.	6.6	21
247	Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 1486-1499.	3.2	41
248	Breast cancer intratumour heterogeneity: current status and clinical implications. <i>Histopathology</i> , 2018, 73, 717-731.	1.6	50
249	Circulating Tumor Cells in Patients Receiving Neoadjuvant Chemotherapy: Refining the Paradigm of Prognosis and Treatment Individualization. <i>Journal of the National Cancer Institute</i> , 2018, 110, 543-544.	3.0	0
250	Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 117-140.	9.6	97
252	Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 439-450.	1.1	15

#	ARTICLE	IF	CITATIONS
253	Prognostic and predictive biomarkers in breast cancer: Past, present and future. <i>Seminars in Cancer Biology</i> , 2018, 52, 56-73.	4.3	284
254	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. <i>Pathobiology</i> , 2018, 85, 146-154.	1.9	33
255	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
256	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. <i>Cancer Research</i> , 2018, 78, 1110-1122.	0.4	85
257	Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs). <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 36-47.	6.6	23
258	Fluorescence detection, enumeration and characterization of single circulating cells <i>in vivo</i> : technology, applications and future prospects. <i>Physics in Medicine and Biology</i> , 2018, 63, 01TR01.	1.6	31
259	Liquid Biopsy in Prostate Cancer: A Case for Comprehensive Genomic Characterization of Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2018, 64, 251-253.	1.5	5
260	EpCAM <sup>high</sup> and EpCAM <sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , 2018, 9, 35705-35716.	0.8	70
262	Acoustic impedance-based size-independent isolation of circulating tumour cells from blood using acoustophoresis. <i>Lab on A Chip</i> , 2018, 18, 3802-3813.	3.1	50
263	Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer. <i>Journal of Laboratory and Precision Medicine</i> , 2018, 3, 33-33.	1.1	0
264	Prognostic Biomarkers for Breast Cancer Metastasis. , 0, , .		1
265	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
266	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 83-95.	0.8	10
267	CTC Technologies and Tools. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1197-1201.	1.1	18
268	Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. <i>Cancers</i> , 2018, 10, 527.	1.7	45
269	Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8â€“9 February 2018. <i>Ecancermedicalscience</i> , 2018, 12, 817.	0.6	3
270	Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. <i>Breast Cancer Research</i> , 2018, 20, 48.	2.2	80
271	Key Enabling Technologies for Point-of-Care Diagnostics. <i>Sensors</i> , 2018, 18, 3607.	2.1	61

#	ARTICLE	IF	CITATIONS
272	Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles. <i>Cancers</i> , 2018, 10, 416.	1.7	30
273	Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. <i>PLoS ONE</i> , 2018, 13, e0204334.	1.1	29
274	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8
275	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. <i>Scientific Reports</i> , 2018, 8, 15931.	1.6	67
276	Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. <i>Journal of Translational Medicine</i> , 2018, 16, 287.	1.8	45
277	The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. <i>Molecular Biology Reports</i> , 2018, 45, 2025-2035.	1.0	6
278	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. <i>Diagnostics</i> , 2018, 8, 59.	1.3	57
279	Liquid Biopsy: From Basic Research to Clinical Practice. <i>Advances in Clinical Chemistry</i> , 2018, 83, 73-119.	1.8	49
280	Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. <i>Advances in Clinical Chemistry</i> , 2018, 83, 121-181.	1.8	35
281	Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. <i>Tumor Biology</i> , 2018, 40, 101042831877616.	0.8	50
282	Microfluidic technologies for circulating tumor cell isolation. <i>Analyst, The</i> , 2018, 143, 2936-2970.	1.7	130
283	The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma. <i>Internal Medicine</i> , 2018, 57, 2695-2700.	0.3	6
284	Health economic impact of liquid biopsies in cancer management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 593-599.	0.7	31
285	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky028.	1.4	10
286	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 9.	1.2	96
287	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	2.3	68
289	Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 718-730.	1.1	31
290	Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. <i>Experimental and Molecular Pathology</i> , 2018, 105, 166-174.	0.9	36



#	ARTICLE	IF	CITATIONS
291	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. <i>BMC Cancer</i> , 2018, 18, 541.	1.1	6
292	Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy. <i>Npj Precision Oncology</i> , 2018, 2, 16.	2.3	6
293	<sup>89</sup> Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2300-2306.	3.3	99
294	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5860-5872.	3.2	44
295	Real-time quantitative PCR detection of circulating tumor cells using tag DNA mediated signal amplification strategy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 204-208.	1.4	10
296	Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1421-1431.	2.3	14
297	Characterizing the Cancer Genome in Blood. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a026880.	2.9	7
298	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEK Prospective Study. <i>Clinical Chemistry</i> , 2019, 65, 1267-1275.	1.5	38
299	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
300	Endometrial Stromal Cells Circulate in the Bloodstream of Women with Endometriosis: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3740.	1.8	8
301	The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy. <i>Cancers</i> , 2019, 11, 1021.	1.7	52
302	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 117, 60-68.	1.3	68
303	<i>in vitro</i> hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. <i>Molecular Oncology</i> , 2019, 13, 2515-2530.	2.1	55
304	Circulating tumour cell RNA characterisation from colorectal cancer patient blood after inertial microfluidic enrichment. <i>MethodsX</i> , 2019, 6, 1512-1520.	0.7	9
305	Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice. <i>Anticancer Research</i> , 2019, 39, 4711-4720.	0.5	5
306	Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. <i>Cells</i> , 2019, 8, 1412.	1.8	45
307	Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma. <i>Molecular Medicine</i> , 2019, 25, 50.	1.9	9
308	Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2019, 19, 1101.	1.1	6

#	ARTICLE	IF	CITATIONS
309	Current progress in the clinical use of circulating tumor cells as prognostic biomarkers. <i>Cancer Cytopathology</i> , 2019, 127, 739-749.	1.4	23
310	CTCs 2020: Great Expectations or Unreasonable Dreams. <i>Cells</i> , 2019, 8, 989.	1.8	29
311	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , 2019, 21, 101.	2.2	54
312	The current status of the clinical utility of liquid biopsies in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1031-1041.	1.5	27
313	Circulating Cell Free Nuclear DNA, Mitochondrial DNA and Global DNA Methylation: Potential Noninvasive Biomarkers for Breast Cancer Diagnosis. <i>Cancer Investigation</i> , 2019, 37, 432-439.	0.6	14
314	Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer. <i>Medical Oncology</i> , 2019, 36, 89.	1.2	11
315	Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 32.	1.8	4
316	Profiling of Invasive Breast Carcinoma Circulating Tumour Cells—Are We Ready for the “Liquid” Revolution?. <i>Cancers</i> , 2019, 11, 143.	1.7	8
317	Microfluidic device for circulating tumor cell quantification and capture. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	0
318	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	0.6	114
319	Liquid biopsy in breast cancer: A comprehensive review. <i>Clinical Genetics</i> , 2019, 95, 643-660.	1.0	210
320	The role of a semi-automated NanoVelcro system in capturing circulating tumor cells and evaluating their prognostic value for gestational choriocarcinoma. <i>Biomaterials Science</i> , 2019, 7, 1200-1210.	2.6	2
321	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	1.7	109
322	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. <i>Drug Discovery Today</i> , 2019, 24, 1715-1719.	3.2	10
323	Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5388-5397.	3.2	27
324	Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. <i>Clinical and Experimental Medicine</i> , 2019, 19, 271-279.	1.9	21
325	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	0.8	21
326	Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. <i>Cancer Research</i> , 2019, 79, 2798-2804.	0.4	111

#	ARTICLE	IF	CITATIONS
327	The biology and clinical potential of circulating tumor cells. <i>Radiology and Oncology</i> , 2019, 53, 131-147.	0.6	53
328	Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 52-66.	0.5	1
329	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
330	Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells. <i>Lab on A Chip</i> , 2019, 19, 1860-1876.	3.1	43
331	Circulating Tumor Cells in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz026.	1.4	63
333	A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients. <i>Cancer Science</i> , 2019, 110, 1695-1704.	1.7	12
334	Diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 108-122.	1.9	89
335	In Vivo Flow Cytometry of Extremely Rare Circulating Cells. <i>Scientific Reports</i> , 2019, 9, 3366.	1.6	40
336	Circulating and Disseminated Tumour Cells in Breast Carcinoma. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 177-183.	0.8	5
337	Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. <i>Cancers</i> , 2019, 11, 342.	1.7	8
338	Feasibility of single-cell analysis of model cancer and foetal cells in blood after isolation by cell picking. <i>Tumor Biology</i> , 2019, 41, 101042831882336.	0.8	1
339	Tumour biomarkers—Tracing the molecular function and clinical implication. <i>Cell Proliferation</i> , 2019, 52, e12589.	2.4	26
341	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. <i>Nature Communications</i> , 2019, 10, 1478.	5.8	80
342	Liquid biopsy and minimal residual disease — latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671
343	Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 573.	3.4	1
344	Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 163.	1.7	13
345	Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. <i>Clinical Chemistry</i> , 2019, 65, 549-558.	1.5	37
346	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	1.6	27

#	ARTICLE	IF	CITATIONS
347	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019, 25, 6089-6097.	3.2	46
348	CTCs as Liquid Biopsy: Where Are We Now?. , 2019, , .		3
350	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	3.2	13
351	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. <i>Scientific Reports</i> , 2019, 9, 17276.	1.6	16
352	Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. <i>Breast Cancer Research</i> , 2019, 21, 121.	2.2	42
353	Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. <i>BMC Cancer</i> , 2019, 19, 1167.	1.1	20
354	&lt;p&gt;First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 10427-10433.	0.9	9
355	Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review. <i>BMC Pulmonary Medicine</i> , 2019, 19, 262.	0.8	11
357	Progress toward liquid biopsies in pediatric solid tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 553-571.	2.7	32
358	Circulating and Disseminated Tumor Cells in Breast Carcinoma. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1320-1327.	0.8	17
359	Magnetic â€œSquashingâ€•of Circulating Tumor Cells on Plasmonic Substrates for Ultrasensitive NIR Fluorescence Detection. <i>Small Methods</i> , 2019, 3, 1800474.	4.6	52
360	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. <i>European Journal of Cancer</i> , 2019, 106, 133-143.	1.3	35
361	Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 76-81.	0.9	1
362	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
363	Current and future perspectives ofÂliquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019, 20, 71-88.	7.7	912
364	Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 437-447.	1.9	133
365	Role of Circulating Tumor Cells in Breast Cancer Patients. , 2019, , 383-392.		0
366	Prognostic and Predictive Role of Circulating Tumor Cells. , 2019, , 181-190.		1

#	ARTICLE	IF	CITATIONS
367	Liquid biopsy: novel technologies and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 312-316.	1.4	35
368	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	86
369	Characterizing Circulating Tumor Cells Isolated from Metastatic Breast Cancer Patients Using Graphene Oxide Based Microfluidic Assay. <i>Advanced Biology</i> , 2019, 3, e1800278.	3.0	19
370	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 380-387.	3.0	101
371	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 155-165.	1.1	11
372	Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periapillary Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 549-558.	2.1	40
373	Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100816.	2.7	62
374	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
375	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
376	Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 111-121.	1.2	22
377	Liquid Biopsy Based on Circulating Cancer-Associated Cells: Bridging the Gap from an Emerging Concept to a Mainstream Tool in Precision Medicine. <i>Advanced Biology</i> , 2020, 4, 1900164.	3.0	4
378	Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform. <i>Advanced Biology</i> , 2020, 4, 1900162.	3.0	19
379	Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. <i>Clinical Chemistry</i> , 2020, 66, 97-104.	1.5	33
380	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020, 23, 193-202.	3.7	11
381	A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells. <i>Micromachines</i> , 2020, 11, 870.	1.4	7
382	Pediatric sarcomas display a variable EpCAM expression in a histology-dependent manner. <i>Translational Oncology</i> , 2020, 13, 100846.	1.7	8
384	The Metastatic Cascade as the Basis for Liquid Biopsy Development. <i>Frontiers in Oncology</i> , 2020, 10, 1055.	1.3	27
385	Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5040.	1.8	28

#	ARTICLE	IF	CITATIONS
386	Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 134.	1.6	17
387	Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1795-1809.	1.3	24
388	Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. <i>Cells</i> , 2020, 9, 1836.	1.8	66
389	The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast—Long-Term Prognostic Significance. <i>Cells</i> , 2020, 9, 1718.	1.8	10
390	Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. <i>Cancers</i> , 2020, 12, 1930.	1.7	128
391	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	1.5	33
392	Predicting therapy response by analysis of metastasis founder cells: emerging perspectives for personalized tumor therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 413-420.	0.4	1
393	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. <i>Frontiers in Immunology</i> , 2020, 11, 2023.	2.2	50
394	Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1027-1037.	0.6	3
395	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	1.9	15
396	Clinical relevance of liquid biopsy in breast cancer: update in 2020. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 913-919.	1.5	13
397	Possible role of circulating tumor cells in early detection of lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 3821-3835.	0.6	8
398	Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. <i>Cancers</i> , 2020, 12, 2361.	1.7	22
399	Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. <i>Cancers</i> , 2020, 12, 3735.	1.7	11
400	Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9460.	1.8	7
402	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1084.	1.7	17
403	Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes. <i>Cancers</i> , 2020, 12, 1111.	1.7	40
404	Detection of Circulating Tumor Cells in Breast Cancer Patients by Nanopore Sensing with Aptamer-Mediated Amplification. <i>ACS Sensors</i> , 2020, 5, 2359-2366.	4.0	43

#	ARTICLE	IF	CITATIONS
405	Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 56.	2.2	25
406	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. <i>Clinical Cancer Research</i> , 2020, 26, 4892-4900.	3.2	5
407	Circulating tumour cells as prognosis predictive markers of neoadjuvant chemotherapy-treated breast cancer patients. <i>Journal of Chemotherapy</i> , 2020, 32, 304-309.	0.7	4
408	Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 815-828.	1.5	4
409	Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3311.	1.3	7
410	Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?. <i>Medical Oncology</i> , 2020, 37, 29.	1.2	34
411	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 61-68.	1.1	15
412	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	40
413	Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1696.	1.8	34
414	Circulating tumor cells: moving forward into clinical applications. <i>Precision Cancer Medicine</i> , 0, 3, 4-4.	1.8	14
415	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66
416	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	3.4	161
417	Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4364.	1.8	4
418	Clinical Significance of Circulating Tumor Cells in Hormone Receptorâ€“positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020, 26, 4911-4920.	3.2	14
419	Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. <i>Biomolecules</i> , 2020, 10, 255.	1.8	52
420	Rapid Detection of Circulating Breast Cancer Cells Using a Multiresonant Optical Fiber Aptasensor with Plasmonic Amplification. <i>ACS Sensors</i> , 2020, 5, 454-463.	4.0	120
421	Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. <i>British Journal of Cancer</i> , 2020, 122, 857-867.	2.9	48
422	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	3.6	447

#	ARTICLE	IF	CITATIONS
423	Affinity-Enhanced CTC-Capturing Hydrogel Microparticles Fabricated by Degassed Mold Lithography. <i>Journal of Clinical Medicine</i> , 2020, 9, 301.	1.0	6
424	Dynamic changes of Receptor activator of nuclear factor- $\kappa$ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. <i>Scientific Reports</i> , 2020, 10, 1288.	1.6	25
425	Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer. <i>Cancer Medicine</i> , 2020, 9, 2290-2298.	1.3	8
426	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1055.	1.7	19
427	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. <i>Biosensors and Bioelectronics</i> , 2020, 162, 112250.	5.3	27
428	Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the $\alpha$ -Universal-CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2. <i>Cells</i> , 2020, 9, 888.	1.8	19
429	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. <i>Molecular Oncology</i> , 2020, 14, 1898-1909.	2.1	11
430	A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23245.	0.9	7
431	Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. <i>Cancer Cell</i> , 2020, 37, 485-495.	7.7	223
432	Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1005.	1.7	5
433	Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2885.	1.8	9
434	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 930.	1.7	7
435	Circulating Tumor Cells in Breast Cancer Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	2
436	Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. <i>European Respiratory Review</i> , 2020, 29, 190052.	3.0	87
437	A novel device to capture circulating tumor cells: Quantification and molecular analysis in lung cancer patients. <i>Journal of Biomaterials Applications</i> , 2020, 35, 49-58.	1.2	2
438	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <i>Cancers</i> , 2020, 12, 848.	1.7	14
439	The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. <i>Cancers</i> , 2020, 12, 867.	1.7	63
440	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	3.4	92



#	ARTICLE	IF	CITATIONS
441	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
442	Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges. <i>Laser and Photonics Reviews</i> , 2021, 15, .	4.4	10
443	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
444	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80
445	Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
446	Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer. <i>Biomedicines</i> , 2021, 9, 48.	1.4	14
447	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	1.7	4
448	Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 337-361.	0.8	6
449	Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110284.	1.4	12
450	Fundamentals of integrated ferrohydrodynamic cell separation in circulating tumor cell isolation. <i>Lab on A Chip</i> , 2021, 21, 1706-1723.	3.1	15
451	Simultaneous biochemical and functional phenotyping of single circulating tumor cells using ultrahigh throughput and recovery microfluidic devices. <i>Lab on A Chip</i> , 2021, 21, 3583-3597.	3.1	9
452	Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability. <i>Cells</i> , 2021, 10, 337.	1.8	5
453	Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine. <i>Cancers</i> , 2021, 13, 728.	1.7	19
454	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
455	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TRENd trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	2.2	14
456	Prospective Assessment of the Association Between Circulating Tumor Cells and Control of Brain Disease After Focal Radiation Therapy of Breast Cancer Brain Metastases. <i>Advances in Radiation Oncology</i> , 2021, 6, 100673.	0.6	3
457	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPe, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021, 13, 44.	3.6	13
458	Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2021, 23, 31.	2.2	39

#	ARTICLE	IF	CITATIONS
459	PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications. <i>Cancers</i> , 2021, 13, 1592.	1.7	11
460	Computational models of cancer cell transport through the microcirculation. <i>Biomechanics and Modeling in Mechanobiology</i> , 2021, 20, 1209-1230.	1.4	5
461	Exosome-based liquid biopsies in cancer: opportunities and challenges. <i>Annals of Oncology</i> , 2021, 32, 466-477.	0.6	405
462	Liquid Biopsy: From Discovery to Clinical Application. <i>Cancer Discovery</i> , 2021, 11, 858-873.	7.7	407
463	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
464	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 488-505.	12.5	91
465	Triple-negative breast cancer: A run-through of features, classification and current therapies (Review). <i>Oncology Letters</i> , 2021, 22, 512.	0.8	52
466	Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer. <i>British Journal of Cancer</i> , 2021, 125, 907-908.	2.9	0
467	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 85.	3.6	21
468	Response to Comment on "Circulating Tumor Cells" New Indicator for Clinical Staging of Patients With Esophageal Cancer by Wenxian Guan. <i>Annals of Surgery</i> , 2021, 274, e914-e915.	2.1	0
469	Detection of cancer metastasis: past, present and future. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 21-28.	1.7	9
470	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2640.	1.7	8
471	Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications. <i>Cancers</i> , 2021, 13, 2668.	1.7	20
472	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77.	2.3	16
473	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602222.	1.3	9
474	Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 697572.	1.3	0
475	Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 196.	3.5	20
476	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. <i>Scientific Reports</i> , 2021, 11, 13441.	1.6	15

#	ARTICLE	IF	CITATIONS
477	Detection Methods and Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 652253.	1.3	36
478	Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions. <i>Cancers</i> , 2021, 13, 2798.	1.7	20
479	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. <i>Cancers</i> , 2021, 13, 2966.	1.7	11
480	The Opportunities and Challenges of Molecular Tagging Next-Generation Sequencing in Liquid Biopsy. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 537-547.	1.6	3
481	Prognostic Value of Venous Invasion Detected by Elastin Stain May Surpass Lymph Node Status in Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 955-963.	0.7	7
482	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1037-1048.	1.5	7
483	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. <i>Cell Reports Medicine</i> , 2021, 2, 100373.	3.3	6
484	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 115.	2.3	33
485	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. <i>Biomedicines</i> , 2021, 9, 1242.	1.4	6
486	Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum. <i>Frontiers in Oncology</i> , 2021, 11, 699401.	1.3	9
487	Circulating Biomarkers in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e319-e331.	1.1	28
488	Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients. <i>Current Oncology</i> , 2021, 28, 3507-3524.	0.9	2
489	Diagnosis, biology and epidemiology of oligometastatic breast cancer. <i>Breast</i> , 2021, 59, 144-156.	0.9	6
490	Microfluidics-based devices and their role on point-of-care testing. , 2022, , 197-224.		1
491	CTCs in Solid Tumors. <i>Clinical Applications of Circulating Tumor Cells in Breast Cancer</i> . , 2021, , 9-25.		0
492	Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. <i>British Journal of Cancer</i> , 2021, 124, 1207-1213.	2.9	31
493	Bone Metastasis of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 105-129.	0.8	90
494	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 147-160.	1.8	8

#	ARTICLE	IF	CITATIONS
495	Introduction“ Biology of Breast Cancer Metastasis and Importance of the Analysis of CTCs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 1-10.	0.8	10
496	Disseminated Tumor Cells and Dormancy in Breast Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 35-43.	0.8	17
497	Relevance of CTC Clusters in Breast Cancer Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 93-115.	0.8	26
498	Liquid Biopsy in Breast Cancer. <i>Current Clinical Pathology</i> , 2017, , 77-84.	0.0	1
499	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 571-580.	1.1	12
500	Could liquid biopsies help deliver better treatment?. <i>Nature</i> , 2020, 579, S6-S8.	13.7	9
501	Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients. <i>Anesthesiology</i> , 2020, 133, 548-558.	1.3	30
504	Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo. <i>Journal of Biomedical Optics</i> , 2019, 24, 1.	1.4	25
505	Recent advances in preoperative management of esophageal adenocarcinoma. <i>F1000Research</i> , 2017, 6, 501.	0.8	1
506	Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model. <i>Biomedical Optics Express</i> , 2020, 11, 3633.	1.5	18
507	A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. <i>PLoS ONE</i> , 2015, 10, e0141166.	1.1	22
508	EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0144535.	1.1	92
509	Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. <i>PLoS ONE</i> , 2016, 11, e0155126.	1.1	54
510	Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 183-187.	0.6	10
511	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. <i>EMBO Molecular Medicine</i> , 2020, 12, e11908.	3.3	77
512	Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review. <i>Medicine and Pharmacy Reports</i> , 2016, 89, 203-211.	0.2	4
513	Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 65993-66002.	0.8	19
514	Diagnostic and prognostic value of serum MACC1 in breast cancer patients. <i>Oncotarget</i> , 2016, 7, 84408-84415.	0.8	21

#	ARTICLE	IF	CITATIONS
515	Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. <i>Oncotarget</i> , 2017, 8, 45544-45565.	0.8	38
516	Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. <i>Oncotarget</i> , 2017, 8, 72755-72772.	0.8	43
517	Down-regulation of traditional oncomiRs in plasma of breast cancer patients. <i>Oncotarget</i> , 2017, 8, 77369-77384.	0.8	32
518	Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients. <i>Oncotarget</i> , 2017, 8, 92483-92496.	0.8	27
519	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. <i>Oncotarget</i> , 2014, 5, 8147-8160.	0.8	83
520	Establishment of a multimer qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	0.8	36
521	Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer. , 2019, 2, 1215-1223.		2
522	Presence of circulating tumor cells is associated with metabolic-related variables in postoperative patients with early-stage breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 340-350.	0.7	5
523	The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 519-529.	0.6	7
524	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	0.5	14
525	Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases. <i>In Vivo</i> , 2016, 30, 879-884.	0.6	13
526	Place des CTC et de l'ADN circulant dans la prise en charge du cancer du sein. <i>Oncologie</i> , 2019, 21, 40-48.	0.2	1
527	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328.	1.3	35
528	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 810-818.	1.4	16
529	Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma. <i>Oncology Reports</i> , 2020, 43, 1525-1535.	1.2	10
530	Circulating tumor cells isolation: the "post-EpCAM era". <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 461-70.	0.7	19
531	CTC enumeration and characterization: moving toward personalized medicine. <i>Annals of Translational Medicine</i> , 2014, 2, 108.	0.7	83
532	Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?. <i>World Journal of Clinical Oncology</i> , 2018, 9, 26-32.	0.9	25

#	ARTICLE	IF	CITATIONS
533	Liquid Biopsy. UNIPA Springer Series, 2021, , 99-122.	0.1	0
534	The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188634.	3.3	43
535	Unmet needs in basic and translational research in Cholangiocarcinoma. <i>Liver Cancer International</i> , 0, , .	0.2	0
536	Metastatic Breast Cancer. , 2016, , 451-474.		0
537	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2016, , 803-817.		0
538	Omics approaches to individual variation: modeling networks and the virtual patient. <i>Dialogues in Clinical Neuroscience</i> , 2016, 18, 253-265.	1.8	4
539	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa). , 2017, , 47-59.		0
540	Mammaerkrankungen. , 2017, , 297-358.		0
541	Micro-array isolation of circulating tumor cells (CTCs): the droplet biopsy chip. , 2017, , .		0
542	Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms. , 2017, 77, .		0
543	Circulating Molecular and Cellular Biomarkers in Cancer. , 0, , 607-656.		1
544	Circulating tumor cells and their clinical significance. <i>Nowotwory</i> , 2017, 67, 243-250.	0.1	1
545	Why is Immunohistochemical Detection of Metastasized Breast Cancer Cells in the Immunocompetent Host Not Always Easy?. <i>Journal of Analytical Oncology</i> , 0, 7, 72-81.	0.1	0
548	Labeling Circulating Tumor Cells with a Folate Receptor Targeted Probe for Diffuse in-vivo Flow Cytometry. , 2019, , .		0
550	Biopsia liquida: una review. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2019, 15, .	0.2	0
552	Methodology for the Isolation and Analysis of CTCs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 45-59.	0.8	6
554	Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA. <i>Oncology Research and Treatment</i> , 2022, 45, 4-11.	0.8	10
556	Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 147-164.	0.8	1

#	ARTICLE	IF	CITATIONS
557	Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 81-91.	0.8	3
558	MAGEA genes as predictors of the outcome of laryngeal squamous cell carcinoma. <i>Oncology Letters</i> , 2020, 20, 59.	0.8	3
559	CELL MEDIATED IMMUNITY IN PATIENTS WITH STAGE II-IV COLORECTAL CANCER WITH OR WITHOUT CIRCULATING TUMOR CELLS. <i>Siberian Journal of Oncology</i> , 2020, 19, 94-98.	0.1	0
560	Notes for developing a molecular test for the full characterization of circulating tumor cells. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 471-8.	0.7	1
561	The potential for liquid biopsies in the precision medical treatment of breast cancer. <i>Cancer Biology and Medicine</i> , 2016, 13, 19-40.	1.4	12
562	Detection and clinical significance of circulating tumor cells in colorectal cancer. <i>Biomarker Research</i> , 2021, 9, 85.	2.8	19
563	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. <i>PLoS ONE</i> , 2021, 16, e0260124.	1.1	26
564	Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 6004.	1.7	6
565	Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering. <i>Biosensors</i> , 2021, 11, 449.	2.3	7
567	State-of-the-art nanotechnologies for the detection, recovery, analysis and elimination of liquid biopsy components in cancer. <i>Nano Today</i> , 2022, 42, 101361.	6.2	24
568	Zirkulierende Tumorzellen: Ist die Metastasierung bald vorhersagbar?. , 0, , .		0
569	Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. <i>Pharmacogenomics</i> , 2022, 23, 119-134.	0.6	1
570	Challenges and future directions. , 2022, , 139-201.		0
571	Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1671.	1.8	18
572	Multimodal CTC detection using stem cell antigen-specific immunosilica particles and immunofluorescent quantum dots. <i>NPG Asia Materials</i> , 2022, 14, .	3.8	8
573	Isolation and Genomic Analysis of Single Circulating Tumor Cell Using Human Telomerase Reverse Transcriptase and Desmoglein-2. <i>Small Methods</i> , 2022, , 2100938.	4.6	1
574	Breast cancer circulating tumor cells with mesenchymal featuresâ€”an unreachable target?. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 81.	2.4	12
575	Breast cancer recurrence: factors impacting occurrence and survival. <i>Irish Journal of Medical Science</i> , 2022, 191, 2501-2510.	0.8	12

#	ARTICLE	IF	CITATIONS
576	Liquid biopsy: the value of different bodily fluids. <i>Biomarkers in Medicine</i> , 2022, 16, 127-145.	0.6	12
577	Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 583-591.	1.1	5
578	Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 725318.	1.3	3
579	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1312.	1.1	6
580	Development of KAM score to predict metastasis and worse survival in breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 5388-5401.	1.4	0
581	Mammaerkrankungen. , 2021, , 297-361.		0
582	Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates. <i>SAGE Open Medicine</i> , 2022, 10, 205031212210778.	0.7	6
583	Morphological Phenotyping of Organotropic Brain- and Bone-Seeking Triple Negative Metastatic Breast Tumor Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790410.	1.8	2
584	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
585	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	1.3	18
586	Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1384.	1.7	33
587	Clinical significance of circulating tumor cells and cell-free DNA in pediatric rhabdomyosarcoma. <i>Molecular Oncology</i> , 2022, 16, 2071-2085.	2.1	7
588	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
589	The potential of liquid biopsy in the management of cancer patients. <i>Seminars in Cancer Biology</i> , 2022, 84, 69-79.	4.3	55
590	Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 437-444.	1.1	16
591	Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1169-1181.	0.9	5
592	Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy. <i>Frontiers in Oncology</i> , 2021, 11, 801173.	1.3	3
593	Circulating tumor cell count: A reliable biomarker for treatment selection in metastatic breast cancer. <i>Thoracic Cancer</i> , 2022, 13, 265-266.	0.8	1



#	ARTICLE	IF	CITATIONS
594	Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination. <i>Nature Communications</i> , 2021, 12, 7300.	5.8	53
595	Modulation of cancer stemness property in head and neck cancer cells via circulatory fluid shear stress. <i>Microfluidics and Nanofluidics</i> , 2022, 26, 1.	1.0	2
598	pH-Responsive Carbon Nanotube Film-Based Microfluidic Chip for Efficient Capture and Release of Cancer Cells. <i>ACS Applied Nano Materials</i> , 2022, 5, 6911-6924.	2.4	11
599	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 421-429.	0.8	9
601	Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. <i>BMJ Open</i> , 2022, 12, e054404.	0.8	4
602	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.1	6
603	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	1.8	4
604	A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
605	Liquid biopsies in primary and secondary bone cancers. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 541-59.	0.9	4
606	Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 1057-1067.	1.1	1
608	Microfluidic Biosensor-Based Devices for Rapid Diagnosis and Effective Anti-cancer Therapeutic Monitoring for Breast Cancer Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 319-339.	0.8	2
609	Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 499-524.	0.8	5
610	The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
611	Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7843.	1.8	15
612	Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?. <i>Theranostics</i> , 2022, 12, 5836-5855.	4.6	7
613	An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
614	Detection of circulating tumor cells: opportunities and challenges. <i>Biomarker Research</i> , 2022, 10, .	2.8	37
615	Mitochondria dysfunction in circulating tumor cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
616	Detection of Circulating Tumor Cells in Cerebrospinal Fluid of Patients with Suspected Breast Cancer Leptomeningeal Metastases: A Prospective Study. <i>Clinical Chemistry</i> , 2022, 68, 1311-1322.	1.5	10
617	Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9535.	1.8	6
618	Circulating tumor cell isolation for cancer diagnosis and prognosis. <i>EBioMedicine</i> , 2022, 83, 104237.	2.7	84
619	Breast cancer stem cells and their role in tumor microenvironment. , 2022, , 221-248.		0
620	The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR+HER2 <sup>+</sup> metastatic breast cancer: a retrospective study. <i>Annals of Translational Medicine</i> , 2022, 10, 901-901.	0.7	0
621	Circulating Tumor-Derived Endothelial Cells: An Effective Biomarker for Breast Cancer Screening and Prognosis Prediction. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	0
622	Liquid biopsy: current technology and clinical applications. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	158
623	Proteomics and liquid biopsy characterization of human EMT-related metastasis in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
624	Detection of Epidermal Growth Factor Receptor Expression in Breast Cancer Cell Lines Using an Ion-Sensitive Field-Effect Transistor in Combination with Enzymatic Chemical Signal Amplification. <i>Journal of the American Chemical Society</i> , 2022, 144, 16545-16552.	6.6	8
625	Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
626	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
627	Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
628	Fluid shear stress enhances proliferation of breast cancer cells via downregulation of the c-subunit of the F1FO ATP synthase. <i>Biochemical and Biophysical Research Communications</i> , 2022, 632, 173-180.	1.0	3
629	Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
630	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
631	Vertical Graphene-Based Biosensor for Tumor Cell Dielectric Signature Evaluation. <i>Micromachines</i> , 2022, 13, 1671.	1.4	5
632	Genomic Profiling and Liquid Biopsies for Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	0
633	Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile. <i>Journal of Clinical Medicine</i> , 2022, 11, 6067.	1.0	3

#	ARTICLE	IF	CITATIONS
634	Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 5378.	1.7	1
635	A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System. <i>Cancers</i> , 2022, 14, 5238.	1.7	16
636	Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases. <i>Clinical and Experimental Metastasis</i> , 2023, 40, 69-77.	1.7	1
637	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. <i>Cancers</i> , 2022, 14, 5668.	1.7	3
638	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
639	Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. , 2022, 10, e005615.		18
640	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 721-735.	1.2	5
641	Biology, vulnerabilities and clinical applications of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2023, 23, 95-111.	12.8	58
642	Technologies for Viable Circulating Tumor Cell Isolation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15979.	1.8	4
643	Detection of Circulating Tumor Cells Using the Attune NxT. <i>International Journal of Molecular Sciences</i> , 2023, 24, 21.	1.8	3
644	Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	5
645	Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cells. <i>Lab on A Chip</i> , 2023, 23, 1561-1575.	3.1	5
646	Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. <i>Cancers</i> , 2023, 15, 96.	1.7	2
647	Multi-Parameter Analysis of Disseminated Tumor Cells (DTCs) in Early Breast Cancer Patients with Hormone-Receptor-Positive Tumors. <i>Cancers</i> , 2023, 15, 568.	1.7	1
648	A simple and sensitive electrochemical biosensor for circulating tumor cell determination based on dual-toehold accelerated catalytic hairpin assembly. <i>Mikrochimica Acta</i> , 2023, 190, .	2.5	3
649	Microfluidic Label-Free Hydrodynamic Separation of Blood Cells: Recent Developments and Future Perspectives. <i>Advanced Materials Technologies</i> , 2023, 8, .	3.0	8
650	Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer. , 0, , .		0
651	A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA. <i>Clinical Chemistry</i> , 2023, 69, 510-518.	1.5	2

#	ARTICLE	IF	CITATIONS
652	Circulating tumour cells: The Good, the Bad and the Ugly. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188863.	3.3	3
653	Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. <i>Molecular Cancer</i> , 2023, 22, .	7.9	19
654	Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value. <i>British Journal of Cancer</i> , 2023, 128, 1742-1752.	2.9	11
655	Circulating Tumor Cell Detection by Liquid Biopsy during Early-Stage Endometrial Cancer Surgery: A Pilot Study. <i>Biomolecules</i> , 2023, 13, 428.	1.8	1
656	Liquid Biopsies, Novel Approaches and Future Directions. <i>Cancers</i> , 2023, 15, 1579.	1.7	18
657	Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. <i>Diagnostics</i> , 2023, 13, 1032.	1.3	0
658	Single-Cell Enzymatic Screening for Epithelial Mesenchymal Transition with an Ultrasensitive Superwetting Droplet Array Microchip. <i>Small Methods</i> , 2023, 7, .	4.6	0
667	Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	1
668	Zirkulierende Tumorzellen. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0
676	Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer. <i>International Review of Cell and Molecular Biology</i> , 2023, , 1-21.	1.6	1
678	Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer. <i>Current Cancer Research</i> , 2023, , 539-564.	0.2	0
679	Tapered Angle Microfluidic Device for Cell Separation Using Hydrodynamic Principle. <i>Communications in Computer and Information Science</i> , 2024, , 13-28.	0.4	0
690	Isolation of Viable Epithelial and Mesenchymal Circulating Tumor Cells from Breast Cancer Patients. <i>Methods in Molecular Biology</i> , 2024, , 43-52.	0.4	0
691	Circulating Tumor Cell Enrichment and Single-Cell Isolation Combining the CellSearch® and DEPArray™ Systems. <i>Methods in Molecular Biology</i> , 2024, , 11-42.	0.4	0
701	Liquid Biopsy. , 2023, , 467-473.		0